Skip to main content
    J

    Jaguar Animal Health Inc (JAGX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.16
    -0.48 (-10.34%)

    Market Cap: $8.09M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    63%(22/35)
    Avg Surprise
    -404.32%
    Streak
    1 Q
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    Reported Aug 19
    		$-15.70N/A+69.89%Beat+99.6%
    Sep 25
    Reported Nov 14
    		$-219.80$-177.80-23.62%Miss+76.1%
    Jun 25
    Reported Aug 14
    		$-259.26$-249.55-3.89%Miss+92.7%
    Mar 25
    Reported May 15
    		$-16.70$-10.82-54.34%Miss+99.5%
    Dec 24
    Reported Mar 31
    		$-4403.00$-647.50-580.00%Miss-13242.4%
    Sep 24
    Reported Nov 12
    		$-918.75N/A+55.70%Beat+95.4%
    Jun 24
    Reported Aug 12
    		$-3535.00$-1050.00-236.67%Miss+90.2%
    Mar 24
    Reported Apr 1
    		$-3459.75$-1575.00-119.67%Miss+97.2%
    Dec 23
    Reported Jan 31
    		$-33.00N/A+55.28%Beat-862.2%
    Sep 23
    Reported Nov 13
    		$-19949.98N/A+69.11%Beat+95.8%
    Jun 23
    Reported Aug 13
    		$-36224.96N/A+54.90%Beat+92.3%
    Mar 23
    Reported May 15
    		$-125474.87$-236250.35+46.89%Beat+87.5%
    Dec 22
    Reported Mar 27
    		$-3.43N/A+64.82%Beat+85.2%
    Sep 22
    Reported Nov 14
    		$-472500.71$-275625.41-71.43%Beat+52.7%
    Jun 22
    Reported Aug 22
    		$-472500.71$-748126.12+36.84%Beat+52.7%
    Mar 22
    Reported May 10
    		$-1000000.00$-708751.06-41.09%Beat+0.0%
    Dec 21
    Reported Mar 11
    		$-23.25$-6.75-244.44%Miss+31.1%
    Sep 21
    Reported Nov 17
    		$-1000000.00$-787501.18-26.98%Beat+0.0%
    Jun 21
    Reported Aug 13
    		$-1000000.00$-354375.57-182.19%Beat+0.0%
    Mar 21
    Reported May 17
    		$-1000000.00$-236250.38-323.28%Beat+0.0%
    Dec 20
    Reported Mar 31
    		$-33.75$-22.50-50.00%Miss+100.0%
    Sep 20
    Reported Nov 16
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Jun 20
    Reported Aug 13
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Mar 20
    Reported Apr 3
    		$-1000000.00$-1000000.00+0.00%Beat-266666566.6%
    Sep 19
    Reported Nov 14
    		$-1000000.00$-1000000.00+0.00%Beat-196078331.4%
    Jun 19
    Reported Aug 14
    		$-1000000.00$-1000000.00+0.00%Beat-1428571528.4%
    Mar 19
    Reported Apr 10
    		$-1000000.00$-1000000.00+0.00%Beat-1904661.9%
    Dec 18
    Reported Mar 13
    		$-0.38$-0.07-435.71%Miss-635.7%
    Sep 18
    Reported Nov 19
    		$-0.51$-0.45-13.33%Miss+99.2%
    Jun 18
    Reported Aug 13
    		$0.07N/A+115.56%Beat+100.1%
    Mar 18
    Reported Apr 9
    		$-52.50$-0.60-8650.00%Miss-950.0%
    Dec 17
    Reported Mar 14
    		$0.07$0.00N/ABeat+100.0%
    Sep 17
    Reported Nov 20
    		$-63.00N/A+53.85%Beat-
    Jun 17
    Reported Aug 9
    		$-126.00$-231.00+45.45%Beat-
    Mar 17
    Reported May 15
    		$-5.00$-0.13-3746.15%Miss-
    Dec 16
    Reported Feb 15
    		$-294.00$-252.00-16.67%Miss-

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-130.80%Operating Margin-620.00%
    ROE-549.00%ROIC-113.34%
    Financial Health
    Debt/Equity2.35xInterest Coverage-6.23x
    Current Ratio0.69xQuick Ratio0.40x
    Trading Statistics
    Beta-0.10Avg Volume6.18M
    52-Week High$1160.2552-Week Low$2.35

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.56
    SMA 20$6.33
    SMA 50$9.28
    SMA 200$137.87
    EMA 10$5.02
    EMA 20$6.06
    EMA 50$12.79
    EMA 200$228.42

    MACD

    Line: -1.60Signal: -1.71Hist: 0.11

    ADX

    ADX: 63.4+DI: 25.2-DI: 5.6

    Aroon & PSAR

    Aroon Up40.0
    Aroon Down20.0
    PSAR$18.38

    Bollinger Bands

    Upper Band$19.97
    Lower Band$-7.30
    %B Position43053%(Upper)
    Band Width0.42

    RSI (14-Day)

    Neutral
    44.7

    Momentum Oscillators

    Stoch %K6.7
    Stoch %D6.1
    Williams %R-92.3
    ROC (10d)-21.8%
    Momentum-1.16
    CCI (20d)-43.1
    MFI (14d)91.7

    Volatility Measures

    ATR (14d)$5.03(121.0%)
    StdDev (20d)6.82
    Hist Vol4267.5%(High)

    Volume Flow

    VWAP$4.21
    OBV185.4M
    AD Line979.5B
    CMF (20d)1.791

    Volume Metrics

    Avg Vol (20d)6.7M
    Vol Ratio0.1x(Low)
    VWMA (20d)$12.16

    Pivot Points

    R3$5.39
    R2$5.11
    R1$4.88
    Pivot Point$4.59
    S1$4.36
    S2$4.08
    S3$3.85

    Advanced Oscillators

    TSI-8.81
    Ultimate Osc36.9
    KST-273.15

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.23M$20.27M$3.23M$3.08M$2.98M$2.21M$3.51M$3.11M$2.72M$2.35M$2.30M$2.81M
    Cost of Revenue$1.03M$1.16M$2.20M$532,000$527,000$515,000$557,000$541,000$427,000$430,000$687,000$514,000
    Gross Profit$194,000$19.11M$1.03M$2.55M$2.45M$1.70M$2.95M$2.57M$2.29M$1.92M$1.61M$2.30M
    Operating Expenses$7.79M$8.93M$22.28M$9.79M$10.46M$11.12M$11.11M$9.83M$9.49M$10.14M$9.17M$11.09M
    R&D$3.34M$3.93M$14.31M$3.66M$3.27M$3.73M$4.53M$4.04M$3.65M$4.31M$3.46M$6.08M
    SG&A$4.45M$4.11M$4.89M$4.13M$4.73M$4.90M$3.86M$3.78M$4.31M$4.38M$3.81M$3.53M
    Operating Income$-7,597,000$10.18M$-21,242,000$-7,238,000$-8,007,000$-9,421,000$-8,157,000$-7,262,000$-7,197,000$-8,215,000$-7,557,000$-8,787,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$3.67M$1.33M$109,000$6,000$1.81M$-56,000$-110,000$-162,000$-108,000$-634,000$248,000$-3,197,000
    Income Before Tax$-12,802,000$8.72M$-23,193,000$-9,648,000$-10,560,000$-10,596,000$-10,234,000$-10,021,000$-9,628,000$-9,368,000$-9,309,000$-7,904,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-12,802,000$8.72M$-23,193,000$-9,648,000$-10,560,000$-10,596,000$-10,234,000$-10,021,000$-9,628,000$-9,368,000$-9,309,000$-7,904,000
    EBITDA$-8,163,000$10.57M$-22,388,000$-9,085,000$-8,197,000$-10,106,000$-9,751,000$-9,587,000$-9,177,000$-9,118,000$-6,746,000$-3,389,000
    EBIT$-9,137,000$10.05M$-23,084,000$-9,642,000$-8,753,000$-10,652,000$-10,344,000$-10,183,000$-9,736,000$-10,002,000$-9,047,000$-11,101,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about JAGX

    News

    Jaguar Health sets October 16 ex-date for dividend on Jaguar Health stock

    Jaguar Health has announced an October 16, 2026 ex-dividend date for its Series R Convertible Preferred Stock. Each preferred share will convert into five common shares on November 2, 2026...

    ad-hoc-news.de•10/15/26•Somewhat-Bullish

    Jaguar Health sets ex-dividend date for Series R preferred stock dividend

    Jaguar Health, Inc. (NASDAQ: JAGX) announced that Nasdaq has set October 16, 2026, as the ex-dividend date for its special stock dividend of Series R Convertible Preferred Stock. The dividend is payable on October 15...

    StreetInsider•10/14/26•Somewhat-Bullish

    Jaguar Health Provides Update Regarding Special Stock Dividend

    Jaguar Health, Inc. has announced an update regarding its special stock dividend, consisting of Series R Convertible Preferred Stock, payable on October 15...

    ACCESS Newswire•10/14/26•Somewhat-Bullish

    Jaguar Health unit presents crofelemer SBS-IF study data at ACG 2026

    Napo Pharmaceuticals, a subsidiary of Jaguar Health (NASDAQ: JAGX), presented preliminary results from an open-label pilot study of crofelemer for adult patients with Type 1 short bowel syndrome with intestinal failure...

    StreetInsider•10/14/26•Somewhat-Bullish

    Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer

    Jaguar Health's family company Napo Pharmaceuticals presented positive preliminary results at the American College of Gastroenterology Annual Scientific Meeting for an open-label pilot study of crofelemer powder in adult...

    Yahoo Finance•10/14/26•Bullish

    JAGX Valuation and Fair Value

    Forward P/E
    200.0x
    PEG
    -0.0x
    P/B
    0.0x
    See GNG's fair value

    JAGX Profitability: Margins, ROIC and FCF

    Gross margin
    82.3%
    Operating margin
    -620.0%
    Net margin
    -130.8%
    ROIC
    -113.3%
    ROE
    -549.0%
    FCF margin
    -24.4%

    JAGX Competitors

    CompanyTicker
    Hoth Therapeutics IncHOTH
    Exicure IncXCUR
    American Shared Hospital ServiceAMS
    OSR Holdings IncOSRH
    Immuron Ltd ADRIMRN
    CNS Pharmaceuticals IncCNSP
    Moleculin Biotech IncMBRX
    Collplant Biotechnologies LtdCLGN

    Sector: Healthcare

    JAGX Bull Case vs Bear Case

    Bear case

    • JAGX has a -130.8% net profit margin.
    • JAGX beat EPS estimates in 25.0% of its last 8 reported quarters.
    • JAGX's quarterly revenue changed -58.9% year over year.

    JAGX Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -111.6%

    Frequently Asked Questions About JAGX

    Does JAGX pay dividends?

    Jaguar Animal Health Inc (JAGX) does not currently pay a regular dividend.

    What is JAGX's market cap?

    Jaguar Animal Health Inc (JAGX) has a market capitalization of $8.09M with a current stock price of $4.16.

    Related stocks

    Sector: Healthcare

    All stocks starting with J

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In